FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1606-1610 June 15, 1995 Number 24 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Enhanced production of fetal hemoglobin lessens the severity of -thalassemia and sickle cell disease. Intravenous infusion of arginine butyrate can increase the number of reticulocytes containing fetal hemoglobin in patients with these disorders, and it has induced a substantial increase in hemoglobin in one patient with thalassemia. We therefore tested the efficacy of this agent in patients with -hemoglobinopathies.

Methods We treated 10 patients with severe -thalassemia or sickle cell disease with arginine butyrate at an initial dose of 500 mg per kilogram of body weight per day (final dose, 2000 mg per kilogram per day), 6 days per week, for a mean (±SD) of 10±1.2 weeks (range, 9 to 13). A hematologic response was defined as an increase in the hemoglobin concentration of at least 2 g per deciliter in patients with thalassemia and as a twofold increase in fetal hemoglobin in patients with sickle cell disease.

Results There were increases in -globin messenger RNA and in reticulocytes containing fetal hemoglobin, but no increases in hemoglobin, in the patients with thalassemia. A small, unsustained increase in fetal hemoglobin was observed in two patients with sickle cell disease. Drug toxicity was minimal at standard doses. One patient had a grand mal seizure after inadvertently receiving 2000 mg of arginine butyrate per kilogram over a period of six hours.

Conclusions Ten weeks of intravenous arginine butyrate did not produce a hematologic response in 10 patients with either severe -thalassemia or sickle cell disease.

Source Information

From the Hospital for Sick Children and the University of Toronto, Toronto (G.D.S., N.F.O.); the University of Minnesota School of Medicine, Minneapolis (G.D.G., J.L., S.Y.); and Johns Hopkins University School of Medicine, Baltimore (G.J.D.).

Address reprint requests to Dr. Olivieri at the Haemoglobinopathy Program, Hospital for Sick Children, Rm. 6324, 555 University Ave., Toronto, ON M5G 1X8, Canada.

Full Text of this Article

Related Letters:

Butyrate Treatment in ß-Hemoglobinopathies
Brauer M., Al-Momen A.-K., Faller D. V., Olivieri N. F.
Extract | Full Text  
N Engl J Med 1995; 333:1287-1288, Nov 9, 1995. Correspondence

This article has been cited by other articles:

• Bhatia, H., Hallock, J. L., Dutta, A., Karkashon, S., Sterner, L. S., Miyazaki, T., Dean, A., Little, J. A. (2009). Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells. Blood 113: 6440-6448 [Abstract] [Full Text]  
• Gabbianelli, M., Morsilli, O., Massa, A., Pasquini, L., Cianciulli, P., Testa, U., Peschle, C. (2008). Effective erythropoiesis and HbF reactivation induced by kit ligand in -thalassemia. Blood 111: 421-429 [Abstract] [Full Text]  
• Mai, A., Jelicic, K., Rotili, D., Di Noia, A., Alfani, E., Valente, S., Altucci, L., Nebbioso, A., Massa, S., Galanello, R., Brosch, G., Migliaccio, A. R., Migliaccio, G. (2007). Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia. Mol. Pharmacol. 72: 1111-1123 [Abstract] [Full Text]  
• Fathallah, H., Weinberg, R. S., Galperin, Y., Sutton, M., Atweh, G. F. (2007). Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood 110: 3391-3397 [Abstract] [Full Text]  
• He, Z., Russell, J. E. (2007). Dynamic posttranscriptional regulation of {epsilon}-globin gene expression in vivo. Blood 109: 795-801 [Abstract] [Full Text]  
• Fathallah, H., Atweh, G. F. (2006). Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease. ASH Education Book 2006: 58-62 [Abstract] [Full Text]  
• Weinberg, R. S., Ji, X., Sutton, M., Perrine, S., Galperin, Y., Li, Q., Liebhaber, S. A., Stamatoyannopoulos, G., Atweh, G. F. (2005). Butyrate increases the efficiency of translation of {gamma}-globin mRNA. Blood 105: 1807-1809 [Abstract] [Full Text]  
• Cao, H., Stamatoyannopoulos, G., Jung, M. (2004). Induction of human {gamma} globin gene expression by histone deacetylase inhibitors. Blood 103: 701-709 [Abstract] [Full Text]  
• Dempsey, N. J., Ojalvo, L. S., Wu, D. W., Little, J. A. (2003). Induction of an embryonic globin gene promoter by short-chain fatty acids. Blood 102: 4214-4222 [Abstract] [Full Text]  
• Witt, O., Monkemeyer, S., Ronndahl, G., Erdlenbruch, B., Reinhardt, D., Kanbach, K., Pekrun, A. (2003). Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101: 2001-2007 [Abstract] [Full Text]  
• Atweh, G. F., DeSimone, J., Saunthararajah, Y., Fathallah, H., Weinberg, R. S., Nagel, R. L., Fabry, M. E., Adams, R. J. (2003). Hemoglobinopathies. ASH Education Book 2003: 14-39 [Abstract] [Full Text]  
• Patnaik, A., Rowinsky, E. K., Villalona, M. A., Hammond, L. A., Britten, C. D., Siu, L. L., Goetz, A., Felton, S. A., Burton, S., Valone, F. H., Eckhardt, S. G. (2002). A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies. Clin. Cancer Res. 8: 2142-2148 [Abstract] [Full Text]  
• Chang, J.-G., Hsieh-Li, H.-M., Jong, Y.-J., Wang, N. M., Tsai, C.-H., Li, H. (2001). Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. USA 98: 9808-9813 [Abstract] [Full Text]  
• Boosalis, M. S., Bandyopadhyay, R., Bresnick, E. H., Pace, B. S., Van DeMark, K., Zhang, B., Faller, D. V., Perrine, S. P. (2001). Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood 97: 3259-3267 [Abstract] [Full Text]  
• He, Z., Russell, J. E. (2001). Expression, purification, and characterization of human hemoglobins Gower-1 ({zeta}2{epsilon}2), Gower-2 ({alpha}2{epsilon}2), and Portland-2 ({zeta}2{beta}2) assembled in complex transgenic-knockout mice. Blood 97: 1099-1105 [Abstract] [Full Text]  
• Skarpidi, E., Vassilopoulos, G., Li, Q., Stamatoyannopoulos, G. (2000). Novel in vitro assay for the detection of pharmacologic inducers of fetal hemoglobin. Blood 96: 321-326 [Abstract] [Full Text]  
• Gabbianelli, M., Testa, U., Massa, A., Pelosi, E., Sposi, N. M., Riccioni, R., Luchetti, L., Peschle, C. (2000). Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate. Blood 95: 3555-3561 [Abstract] [Full Text]  
• Witzig, T. E., Timm, M., Stenson, M., Svingen, P. A., Kaufmann, S. H. (2000). Induction of Apoptosis in Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with Chemotherapeutic Agents. Clin. Cancer Res. 6: 681-692 [Abstract] [Full Text]  
• Smith, R. D., Li, J., Noguchi, C. T., Schechter, A. N. (2000). Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood 95: 863-869 [Abstract] [Full Text]  
• Olivieri, N. F. (1999). The {beta}-Thalassemias. NEJM 341: 99-109 [Full Text]  
• Heerdt, B. G., Houston, M. A., Anthony, G. M., Augenlicht, L. H. (1999). Initiation of Growth Arrest and Apoptosis of MCF-7 Mammary Carcinoma Cells by Tributyrin, a Triglyceride Analogue of the Short-Chain Fatty Acid Butyrate,Is Associated with Mitochondrial Activity. Cancer Res. 59: 1584-1591 [Abstract] [Full Text]  
• Steinberg, M. H. (1999). Management of Sickle Cell Disease. NEJM 340: 1021-1030 [Full Text]  
• Ikuta, T., Kan, Y. W., Swerdlow, P. S., Faller, D. V., Perrine, S. P. (1998). Alterations in Protein-DNA Interactions in the gamma -Globin Gene Promoter in Response to Butyrate Therapy. Blood 92: 2924-2933 [Abstract] [Full Text]  
• Gorman, L., Suter, D., Emerick, V., Schumperli, D., Kole, R. (1998). Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc. Natl. Acad. Sci. USA 95: 4929-4934 [Abstract] [Full Text]  
• Bunn, H. F. (1997). Pathogenesis and Treatment of Sickle Cell Disease. NEJM 337: 762-769 [Full Text]  
• RUBENSTEIN, R. C., ZEITLIN, P. L. (1997). A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in Delta F508-Homozygous Cystic Fibrosis Patients . Partial Restoration of Nasal Epithelial CFTR Function. Am. J. Respir. Crit. Care Med. 157: 484-490 [Abstract] [Full Text]  
• Sierakowska, H., Sambade, M. J., Agrawal, S., Kole, R. (1996). Repair of thalassemic human beta -globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 93: 12840-12844 [Abstract] [Full Text]  
• Brauer, M., Al-Momen, A.-K., Faller, D. V., Olivieri, N. F. (1995). Butyrate Treatment in {beta}-Hemoglobinopathies. NEJM 333: 1287-1288 [Full Text]  
• Ikuta, T., Ausenda, S., Cappellini, M. D. (2001). Mechanism for fetal globin gene expression: Role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc. Natl. Acad. Sci. USA 98: 1847-1852 [Abstract] [Full Text]